Background/Aims: This study aimed to compare the outcomes of patients who received systemic chemotherapy or chemoradiotherapy as adjuvant therapies following pancreatic adenocarcinoma resection. Methods: We reviewed the medical records of 40 patients with locoregional pancreatic adenocarcinoma who underwent tumor resection at Pusan National University Hospital between 2008 and 2012. Results: Twenty-nine patients were treated with adjuvant therapy comprising either systemic chemotherapy or chemoradiotherapy after curative-intent surgery. Adjuvant therapy (p=0.025) and complete resection (p=0.043) were associated with longer overall survival. There was no significant difference between chemotherapy and chemoradiotherapy in terms of extending overall survival; however, patients who received chemotherapy had significantly higher survival rates than those who received no adjuvant therapy at all (p=0.012). Conclusions: Adjuvant therapies improve the prognoses of patients with resected pancreatic adenocarcinoma; moreover, chemotherapy produced more favorable outcomes than chemoradiotherapy. Korean J Pancreas Biliary Tract 2018;23(3):108-115 
INTRODUCTION
The 5-year relative survival rate of patients with cancer, Cancer-specific survival rates in patients with pancreatic cancer, which is the fifth leading cause of cancer-related death in Korea, have been slow to improve. Limitations in early detection and the lack of effective therapeutic options substantially contribute to poor prognosis. 3 However, most patients who were diagnosed early and underwent complete resection still died of the disease. Therefore, it is important to improve post-resection survival as well as early detection.
Based on the results of numerous trials, several pancreatic cancer guidelines recommend adjuvant therapy for all patients with resected pancreatic cancer. [4] [5] [6] [7] [8] [9] However, there is no definite standard regarding the optimal timing and duration of adjuvant therapy. There is also no established standard on the use of chemotherapy alone vs chemoradiotherapy. While some experts suggest that concurrent chemoradiotherapy would be superior to chemotherapy, the survival benefits provided by chemoradiotherapy have not been conclusively shown. The ongoing RTOG 0848 trial, which is investigating the benefits of chemoradiotherapy when administered in sequence with systemic chemotherapy will likely provide critical data in this regard. In this context, our study aimed to compare the effectiveness of systemic chemotherapy versus chemoradiotherapy in the adjuvant setting.
METHODS

Patients
We reviewed the medical records of 40 patients with pan- 
Statistical analysis
The Kaplan-Meier method was used to estimate disease- (Fig. 1 ).
Predictive factors for treatment
On univariate analysis, older age (≥65 years) at diagnosis, lymph node metastasis, complete resection, and adjuvant therapy were not significantly correlated with DFS. Fig. 2 ).
Adjuvant treatment method
On subgroup analysis of the 29 patients who underwent adjuvant therapy, neither systemic chemotherapy nor chemoradiotherapy had a survival advantage relative to the other (DFS, 10.1 vs. 8.7 months, respectively, p =0.73; OS, 
Adverse events
Adverse events during treatment were reported in 18 of 29 patients (62.1%) who underwent adjuvant therapy. The common adverse events were neutropenia, thrombocytopenia, anorexia, and asthenia. Grade 3/4 adverse events were more frequently reported in the chemoradiotherapy group than in the chemotherapy group; however, this difference was not significant (Table 4) . Patients who experienced these toxicities were treated via conservative methods.
DISCUSSION
Currently, surgical resection offers the only chance for cure in patients with nonmetastatic pancreatic cancer. Only 10-20% of patients have potentially resectable disease at diagnosis; 12 however, 60-80% of patients experience recurrence despite curative surgery for pancreatic adenocarcinoma and die of metastatic disease. 13, 14 For this reason, adjuvant treatment after successful tumor resection has been studied ( 14 reported that combining radiation and chemotherapy was effective (GITSG and EORTC40891 trials). Based on these results, adjuvant therapy is now recommended by several guidelines. [4] [5] [6] In our study, the adjuvant therapy produced better outcomes than surgery-alone. Regarding nodal status, which is one of the most important prognostic factors after complete pancreatic cancer resection, the 5-year survival rate after pancreaticoduodenectomy is only 10% for patients with node-positive disease and 30% for those with node-negative disease. 16 When our data were analyzed using a multivariate Cox regression model applying known prognostic factors including nodal status, more favorable outcomes were observed in patients who received adjuvant therapy as well.
Comparisons of the effectiveness of chemotherapy vs.
chemoradiotherapy have yielded conflicting results, and no standard has been established as to which regimen should be used. Likewise, our data also did not produce any definitive conclusions; however, patients who received chemotherapy showed a significantly prolonged OS over those who did not receive any adjuvant therapy, while those who received chemoradiotherapy did not. Similar results were obtained in other large-scale studies. 8, 15 Therefore, chemotherapy may be preferable over chemoradiotherapy as an adjuvant treatment. To explain the differences in OS in the absence of significant differences in DFS, further studies of factors such as regimen-associated toxicity and effect of palliative therapy after relapse are required.
Gemcitabine or 5-FU is often used when administering chemoradiotherapy; the recent RTOG 9704 trial showed no significant difference between the 2 agents. 17 According to several studies and a meta-analysis published in 2013, 5-FU and gemcitabine are considered the most effective adjuvant chemotherapy regimens for patients with resected pancreatic cancer. 18, 19 Results from the recent ESPAC-4 trial indicated that adding capecitabine to gemcitabine was better than gemcitabine alone. 20 Recently, Hsieh et al. 21 reported a cohort study performed with propensity score matching in Taiwan in which 588 patients were divided into 3 groups: adjuvant chemoradiotherapy, sequential chemotherapy-radiotherapy, and chemotherapy. Their study showed that adjuvant chemoradiotherapy (HR, 0.398) and sequential chemotherapy-radiotherapy (HR, 0.307) showed improved survival over adjuvant chemotherapy alone. All treatment regimens included intensitymodulated radiotherapy, which they claimed contributed to minimizing toxicities from administering combination radiotherapy and chemotherapy and to improving survival.
However, it is also a retrospective study and has limitations for a conclusion. A large-scale prospective study of this method is currently underway and we need to wait for the result.
Our study had several limitations. First, owing to its small number of patients, retrospective nature, and single-center setting, the results carried insufficient statistical power. Second, the patients' performance statuses, tumor locations, and surgical methods were not considered; furthermore, the patients did not receive homogeneous chemotherapy and chemoradiotherapy regimens.
In conclusion, we found that adjuvant therapies had a positive effect on the prognosis of patients with resected pancreatic adenocarcinoma and that adjuvant chemotherapy produced more favorable OS outcomes than chemora- 
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